Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Iron overload
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== Medication === Medications are used for those unable to tolerate routine blood draws, there are [[chelating]] agents available for use.<ref>{{Cite journal| doi = 10.1021/cr00097a011| volume = 89| issue = 7| pages = 1563β79| last = Miller| first = Marvin J.| title = Syntheses and therapeutic potential of hydroxamic acid based siderophores and analogs| journal = Chemical Reviews| date = 1989-11-01}}</ref> The drug [[deferoxamine]] binds with iron in the bloodstream and enhances its elimination in urine and faeces. Typical treatment for chronic iron overload requires subcutaneous injection over a period of 8β12 hours daily.{{citation needed|date=May 2015}} Two newer [[Chelation therapy|iron-chelating drugs]] that are licensed for use in patients receiving regular blood transfusions to treat [[thalassaemia]] (and, thus, who develop iron overload as a result) are [[deferasirox]] and [[deferiprone]].<ref>{{cite journal|vauthors=Choudhry VP, Naithani R |title=Current status of iron overload and chelation with deferasirox |journal=Indian J Pediatr |volume=74 |issue=8 |pages=759β64 |year=2007 |pmid=17785900 |doi=10.1007/s12098-007-0134-7|s2cid=19930076 }}</ref><ref>{{cite journal|last1=Hoffbrand|first1=A. V.|title=Role of deferiprone in chelation therapy for transfusional iron overload|journal=Blood|date=20 March 2003|volume=102|issue=1|pages=17β24|doi=10.1182/blood-2002-06-1867|pmid=12637334|doi-access=free}}</ref>
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)